Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 842-852

  Niimi, K ^a   Monk, B C ^a   Hirai, A ^b,c   Hatakenaka, K ^d   Umeyama, T ^b   Lamping, E ^a   Maki, K ^d   Tanabe, K ^b   Kamimura, T ^e   Ikeda, F ^d,f   Uehara, Y ^b,g   Kano, R ^c   Hasegawa, A ^c   Cannon, R D ^a   Niimi, M ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d ASTELLAS PHARMA INC   (Japan)

^e HARASANSHIN HOSPITAL   (Japan)

^f LSI MEDIENCE CORPORATION   (Japan)

^g IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

C. albicans; Drug resistance; Echinocandins

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; ECHINOCANDIN; MICAFUNGIN; ANTIFUNGAL AGENT; FUNGAL DNA; FUNGAL PROTEIN; GLUCAN SYNTHASE; GLUCOSYLTRANSFERASE; LIPOPEPTIDE;

ALLELE; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; DNA SEQUENCE; ENZYME ACTIVITY; FUNGAL GENE; FUNGAL STRAIN; GENE MUTATION; GSC1 FUNGAL GENE; HETEROZYGOSITY LOSS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; ANIMAL; CASE REPORT; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; HUMAN; MALE; METABOLISM; MICROBIOLOGICAL EXAMINATION; MISSENSE MUTATION; MOLECULAR GENETICS; PROTEIN PROCESSING;

ADULT; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CATALYTIC DOMAIN; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HUMANS; LIPOPEPTIDES; LOSS OF HETEROZYGOSITY; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PROTEIN PROCESSING, POST-TRANSLATIONAL; SEQUENCE ANALYSIS, DNA;

EID: 77953710273     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq073     Document Type: Article

References (54)

1. Douglas CM. Fungal β(1,3)-D-glucan synthesis. Med Mycol 2001; 39 Suppl 1: 55-66.
2. Tawara S, Ikeda F, Maki K et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
3. Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40: 2228-30.
4. Messer SA, Diekema DJ, Boyken L et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006; 44: 324-6.
5. Pfaller MA, Messer SA, Boyken L et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 2003; 41: 5729-31.
6. Garcia-Effron G, Katiyar SK, Park S et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-12.
7. Pfaller MA, Messer SA, Boyken L et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol 2004; 42: 3117-9.
8. Kang MS, Cabib E. Regulation of fungal cell wall growth: a guanine nucleotide-binding, proteinaceous component required for activity of (1→3)-β-D-glucan synthase. Proc Natl Acad Sci USA 1986; 83: 5808-12.
9. Mol PC, Park HM, Mullins JT et al. A GTP-binding protein regulates the activity of (1→3)-β-glucan synthase, an enzyme directly involved in yeast cell wall morphogenesis. J Biol Chem 1994; 269: 31267-74.
10. Mio T, Adachi-Shimizu M, Tachibana Y et al. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in β-1,3-glucan synthesis. J Bacteriol 1997; 179: 4096-105.
11. Douglas CM, D'Ippolito JA, Shei GJ et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997; 41: 2471-9.
12. Liu TT, Lee RE, Barker KS et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother 2005; 49: 2226-36.
13. Braun BR, van Het Hoog M, d'Enfert C et al. A human-curated annotation of the Candida albicans genome. PLoS Genet 2005; 1: 36-57.
14. Ishihara S, Hirata A, Nogami S et al. Homologous subunits of 1,3-β-glucan synthase are important for spore wall assembly in Saccharomyces cerevisiae. Eukaryot Cell 2007; 6: 143-56.
15. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53: 112-22.
16. Kondoh O, Tachibana Y, Ohya Y et al. Cloning of the RHO1 gene from Candida albicans and its regulation of β-1,3-glucan synthesis. J Bacteriol 1997; 179: 7734-41.
17. Mazur P, Baginsky W. In vitro activity of 1,3-β-D-glucan synthase requires the GTP-binding protein Rho1. J Biol Chem 1996; 271: 14604-9.
18. Kurtz MB, Abruzzo G, Flattery A et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 1996; 64: 3244-51.
19. Douglas CM, Marrinan JA, Li W et al. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-β-D-glucan synthase. J Bacteriol 1994; 176: 5686-96.
20. Moudgal V, Little T, Boikov D et al. Multiechinocandin-and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-9.
21. Miller CD, Lomaestro BW, Park S et al. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006; 26: 877-80.
22. Baixench MT, Aoun N, Desnos-Ollivier M et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007; 59: 1076-83.
23. Hernandez S, Lopez-Ribot JL, Najvar LK et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382-3.
24. Laverdiere M, Lalonde RG, Baril JG et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705-8.
25. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50: 2892-4.
26. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50: 2058-63.
27. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-73.
28. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
29. Rocha EM, Garcia-Effron G, Park S et al. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2007; 51: 4174-6.
30. Cleary JD, Garcia-Effron G, Chapman SW et al. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 2008; 52: 2263-5.
31. Desnos-Ollivier M, Bretagne S, Raoux D et al. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother 2008; 52: 3092-8.
32. Kaneko A, Umeyama T, Hanaoka N et al. Tandem affinity purification of the Candida albicans septin protein complex. Yeast 2004; 21: 1025-33.
33. Hanaoka N, Umeyama T, Ueno K et al. A putative dual-specific protein phosphatase encoded by YVH1 controls growth, filamentation and virulence in Candida albicans. Microbiology 2005; 151: 2223-32.
34. Umeyama T, Kaneko A, Nagai Y et al. Candida albicans protein kinase CaHsl1p regulates cell elongation and virulence. Mol Microbiol 2005; 55: 381-95.
35. Gietz RD, Woods RA. Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol 2002; 350: 87-96.
36. Hatano K, Morishita Y, Nakai T et al. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 2002; 55: 219-22.
37. Lamping E, Monk BC, Niimi K et al. Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell 2007; 6: 1150-65.
38. Bartizal C, Odds FC. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother 2003; 47: 2100-7.
39. Odabasi Z, Paetznick V, Rex JH et al. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 2007; 51: 4214-6.
40. Paderu P, Garcia-Effron G, Balashov S et al. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51: 2253-6.
41. Wiederhold NP, Grabinski JL, Garcia-Effron G et al. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother 2008; 52: 4145-8.
42. Pfeiffer CD, Garcia-Effron G, Zaas AK et al. Breakthrough invasive candidiasis on micafungin. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 12-15 September, 2009. Abstract M-1243. American Society for Microbiology, Washington, DC, USA.
43. Roemer T, Jiang B, Davison J et al. Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol Microbiol 2003; 50: 167-81.
44. Mazur P, Morin N, Baginsky W et al. Differential expression and function of two homologous subunits of yeast 1,3-β-D-glucan synthase. Mol Cell Biol 1995; 15: 5671-81.
45. Garcia-Effron G, Lee S, Park S et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-Dglucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009; 53: 3690-9.
46. Xu D, Jiang B, Ketela T et al. Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS Pathog 2007; 3: e92.
47. Scherer S, Magee PT. Genetics of Candida albicans. Microbiol Rev 1990; 54: 226-41.
48. Odds FC, Davidson AD, Jacobsen MD et al. Candida albicans strain maintenance, replacement, and microvariation demonstrated by multilocus sequence typing. J Clin Microbiol 2006; 44: 3647-58.
49. Coste A, Selmecki A, Forche A et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 2007; 6: 1889-904.
50. Dunkel N, Blass J, Rogers PD et al. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol 2008; 69: 827-40.
51. Tsang PW, Cao B, Siu PY et al. Loss of heterozygosity, by mitotic gene conversion and crossing over, causes strain-specific adenine mutants in constitutive diploid Candida albicans. Microbiology 1999; 145: 1623-9.
52. del Pozo L, Osaba L, Corchero J et al. A single nucleotide change in the MNR1 (VCX1/HUM1) gene determines resistance to manganese in Saccharomyces cerevisiae. Yeast 1999; 15: 371-5.
53. Lesage G, Sdicu AM, Menard P et al. Analysis of β-1,3-glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin. Genetics 2004; 167: 35-49.
54. Markovich S, Yekutiel A, Shalit I et al. Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2004; 48: 3871-6.